COMPARISON OF INTRAVITREAL BEVACIZUMAB FOLLOWED BY RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
PURPOSE: To compare outcomes after switching from intravitreal bevacizumab (Avastin) to ranibizumab (Lucentis) in patients with neovascular age-related macular degeneration (AMD). METHODS: A retrospective review was performed of patients with neovascular AMD who were switched from treatment with intravitreal bevacizumab to intravitreal ranibizumab once ranibizumab became commercially available. All reviewed patients had at least three bevacizumab injections before being switched to ranibizumab. The treatment outcomes included comparisons of visual acuity and dosing frequency while receiving both drugs. RESULTS: Eighty-four eyes met the inclusion criteria. Mean baseline visual acuity was 20/100. Mean duration of bevacizumab treatment was 7.1 months followed by 7.3 months with ranibizumab (P = 0.68). Best-obtained visual acuity during treatment was 20/63 with bevacizumab and 20/63 with ranibizumab (P = 0.5). Last mean visual acuity after receiving bevacizumab at the time of the first ranibizumab injection was 20/80. Mean visual acuity at the last ranibizumab follow-up visit was 20/80 (P = 0.49). Mean injection rates per month while receiving bevacizumab and ranibizumab were 0.66 (P = 0.98). CONCLUSION: In this subset of patients with neovascular AMD switched from bevacizumab to ranibizumab therapy, there were no apparent differences in visual acuity outcomes or injection rates. Larger prospective studies are under way to directly compare these drugs for the treatment of neovascular AMD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Wu, L., Martínez-Castellanos, M. A., Quiroz-Mercado, H., Arevalo, J. F., Berrocal, M. H., Farah, M. E., Maia, M., Roca, J. A., Rodriguez, F. J., & for the Pan American Collaborative Retina Group (PACORES) (2007) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-007-0660-z · Cited by 456
The Price of Sight — Ranibizumab, Bevacizumab, and the Treatment of Macular Degeneration
Steinbrook, R. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068185 · Cited by 255
Cited by
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
“Although intriguing, this finding has not been universally observed across all clinical studies (Stepien et al., 2009).”
ResultsiRNA therapeutics: a clinical reality
Saw, P. E., & Song, E.-W. (2020) · Science China Life Sciences · doi:10.1007/s11427-018-9438-y · Cited by 291
Yonekawa, Y., Andreoli, C., Miller, J. B., Loewenstein, J. I., Sobrin, L., Eliott, D., Vavvas, D. G., Miller, J. W., & Kim, I. K. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.03.030 · Cited by 166
Uveitis Following Intravitreal Bevacizumab: A Non-Infectious Cluster
Kay, C. N., Tarantola, R. M., Gehrs, K. M., Folk, J. C., Mahajan, V. B., Boldt, H. C., Syed, N. A., & Russell, S. R. (2011) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/15428877-20110603-04 · Cited by 37
Metadata
- Authors
- STEPIEN, K. E., ROSENFELD, P. J., PULIAFITO, C. A., FEUER, W., SHI, W., AL-ATTAR, L., DUBOVY, S. R., MURRAY, T. G., DAVIS, J. L., LEE, W.-H., SCHWARTZ, S. G., SMIDDY, W. E., BERROCAL, A. M., & FLYNN, H. W.
- Venue
- Retina
- Published
- 2009-09
- Volume
- 29
- Issue
- 8
- Pages
- 1067-1073
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W1995044506
- Cited by
- 48
- References
- 3
- FWCI
- 6.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: COMPARISON OF INTRAVITREAL BEVACIZUMAB FOLLOWED BY RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. https://app.cochat.ai/papers/10.1097/iae.0b013e3181b1bb06
- The paper
- STEPIEN, K. E., ROSENFELD, P. J., PULIAFITO, C. A., FEUER, W., SHI, W., AL-ATTAR, L., DUBOVY, S. R., MURRAY, T. G., DAVIS, J. L., LEE, W.-H., SCHWARTZ, S. G., SMIDDY, W. E., BERROCAL, A. M., & FLYNN, H. W. (2009). COMPARISON OF INTRAVITREAL BEVACIZUMAB FOLLOWED BY RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. https://doi.org/10.1097/iae.0b013e3181b1bb06
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.